CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Aspirin 81 mgWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2663 Vitamin D Wiki 0.38

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D004211 Disseminated Intravascular Coagulation NIH 0.50
D014808 Vitamin D Deficiency NIH 0.45

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0005521 Disseminated intravascular coagulation HPO 0.50
HP:0100512 Low levels of vitamin D HPO 0.45

There is one clinical trial.

Clinical Trials


1 The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy. Untreated CAC leads to microangiopathic thromboses, causing multiple systems organ failure and consuming enormous healthcare resources. Identifying strategies to prevent CAC are therefore crucial to reducing COVID-19 hospitalization rates. The pathogenesis of CAC is unknown, but there are major overlaps between severe COVID-19 and vitamin D insufficiency (VDI). We hypothesize that VDI is a major underlying contributor to CAC. Preliminary data from severe COVID-19 patients in New Orleans support this hypothesis. The purpose of the proposed multi-center, prospective, randomized controlled trial is to test the hypothesis that low-risk, early treatment with aspirin and vitamin D in COVID-19 can mitigate the prothrombotic state and reduce hospitalization rates.

NCT04363840 COVID Vitamin D Deficiency Coagulopathy Disseminated Intravascular Coagulation Drug: Aspirin 81 mg Dietary Supplement: Vitamin D
MeSH:Disseminated Intravascular Coagulation Vitamin D Deficiency
HPO:Disseminated intravascular coagulation Low levels of vitamin D

Primary Outcomes

Description: Hospitalization for COVID-19 symptoms

Measure: Hospitalization

Time: 2 weeks


Related HPO nodes (Using clinical trials)